These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12975087)

  • 21. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
    Ren S; Klump W
    Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
    Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
    Hayes DF; Bast RC; Desch CE; Fritsche H; Kemeny NE; Jessup JM; Locker GY; Macdonald JS; Mennel RG; Norton L; Ravdin P; Taube S; Winn RJ
    J Natl Cancer Inst; 1996 Oct; 88(20):1456-66. PubMed ID: 8841020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic evaluation of candidate blood markers for detecting ovarian cancer.
    Palmer C; Duan X; Hawley S; Scholler N; Thorpe JD; Sahota RA; Wong MQ; Wray A; Bergan LA; Drescher CW; McIntosh MW; Brown PO; Nelson BH; Urban N
    PLoS One; 2008 Jul; 3(7):e2633. PubMed ID: 18612378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
    Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
    Tamir A; Jag U; Sarojini S; Schindewolf C; Tanaka T; Gharbaran R; Patel H; Sood A; Hu W; Patwa R; Blake P; Chirina P; Oh Jeong J; Lim H; Goy A; Pecora A; Suh KS
    J Ovarian Res; 2014 Dec; 7():109. PubMed ID: 25477184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers.
    Kosmahl M; Wagner J; Peters K; Sipos B; Klöppel G
    Am J Surg Pathol; 2004 Mar; 28(3):339-46. PubMed ID: 15104296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases.
    Yan Z; Hui P
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):75-9. PubMed ID: 19956063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of clinical utility of tumor markers: a tumor marker utility grading system.
    Hayes DF
    Recent Results Cancer Res; 1998; 152():71-85. PubMed ID: 9928548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of tumour markers in serous effusions: a validation study.
    Trapé J; Molina R; Sant F; Montesinos J; Arnau A; Franquesa J; Blavia R; Martín E; Marquilles E; Perich D; Pérez C; Roca JM; Doménech M; López J; Badal JM
    Tumour Biol; 2012 Oct; 33(5):1661-8. PubMed ID: 22678976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
    Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
    Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.